Tien Hoang

3.6k total citations · 2 hit papers
70 papers, 2.4k citations indexed

About

Tien Hoang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Tien Hoang has authored 70 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Tien Hoang's work include Lung Cancer Treatments and Mutations (30 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Lung Cancer Research Studies (15 papers). Tien Hoang is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Lung Cancer Research Studies (15 papers). Tien Hoang collaborates with scholars based in United States, Spain and United Kingdom. Tien Hoang's co-authors include Joan H. Schiller, Mark A. Socinski, David H. Johnson, Ronghui Xu, Philip Bonomi, Mark L. McCleland, Shawn W. Sun, Ross A. Soo, Paul M. Harari and Delvys Rodríguez‐Abreu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Tien Hoang

64 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

2020 405 citations Delvys Rodríguez‐Abreu, Maen Hussein et al. Journal of Thoracic Oncology profile →
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tien Hoang United States	22	1.8k	1.4k	414	276	227	70	2.4k
Michael Millward Australia	25	1.7k 1.0×	1.1k 0.8×	1.1k 2.8×	250 0.9×	331 1.5×	43	2.9k
Esma Saâda-Bouzid France	23	1.4k 0.8×	951 0.7×	288 0.7×	319 1.2×	240 1.1×	88	2.0k
Sreenivasa Nattam United States	20	1.9k 1.1×	1.0k 0.7×	760 1.8×	182 0.7×	378 1.7×	42	2.6k
G. Robinet France	23	2.1k 1.2×	2.3k 1.6×	522 1.3×	102 0.4×	325 1.4×	110	3.0k
Penelope A. Bradbury Canada	29	1.1k 0.6×	1.1k 0.8×	604 1.5×	150 0.5×	419 1.8×	112	2.0k
Eckart Laack Germany	23	2.0k 1.1×	2.2k 1.6×	619 1.5×	135 0.5×	408 1.8×	61	3.0k
C. Lewanski United Kingdom	16	2.4k 1.4×	1.7k 1.2×	354 0.9×	587 2.1×	389 1.7×	41	3.0k
Anas Gazzah France	22	1.3k 0.7×	861 0.6×	553 1.3×	305 1.1×	355 1.6×	99	2.1k
Jill Walker United Kingdom	19	1.3k 0.7×	945 0.7×	326 0.8×	209 0.8×	590 2.6×	58	1.7k
V.A. Miller United States	22	2.1k 1.2×	1.6k 1.1×	924 2.2×	218 0.8×	508 2.2×	83	3.0k

Countries citing papers authored by Tien Hoang

Since Specialization

Citations

This map shows the geographic impact of Tien Hoang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tien Hoang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tien Hoang more than expected).

Fields of papers citing papers by Tien Hoang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tien Hoang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tien Hoang. The network helps show where Tien Hoang may publish in the future.

Co-authorship network of co-authors of Tien Hoang

This figure shows the co-authorship network connecting the top 25 collaborators of Tien Hoang. A scholar is included among the top collaborators of Tien Hoang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tien Hoang. Tien Hoang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thiolat, Allan, Muriel Brengues, José L. Cohen, et al.. (2025). Individual radiosensitivity testing in 2025: Current advances and future directions for personalized radiotherapy. Critical Reviews in Oncology/Hematology. 216. 104948–104948.

Zhang, Lei, Sunny H. Kim, Tien Hoang, et al.. (2025). Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases. Biomedicine & Pharmacotherapy. 189. 118274–118274.

Psyrri, Amanda, Christophe Le Tourneau, Arunee Dechaphunkul, et al.. (2025). 1348MO SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN). Annals of Oncology. 36. S776–S777.

Hoang, Tien, Lei Zhang, Sunny H. Kim, et al.. (2025). Preclinical assessment of genetically modified exosomes for colorectal cancer immunotherapy. Journal of Controlled Release. 389. 114425–114425. 1 indexed citations

Duong, Hai, Tin Truong, Tien Hoang, & Bac Le. (2024). U-HPAUSM: Mining high probability average utility sequences in uncertain quantitative sequential databases. Engineering Applications of Artificial Intelligence. 141. 109742–109742.

Herbst, Roy S., Daniel Ruderman, James F. Conway, et al.. (2023). OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell Scoring on SP263-Stained Whole Imaging Slides from IMpower110. Journal of Thoracic Oncology. 18(11). S79–S80. 2 indexed citations

Krishnan, Sreenath M., Lena E. Friberg, François Mercier, et al.. (2023). Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical Pharmacology & Therapeutics. 113(4). 851–858. 8 indexed citations

Wainberg, Zev A., Ignacio Matos, Jean‐Pierre Delord, et al.. (2021). LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Annals of Oncology. 32. S227–S228. 15 indexed citations

Cho, B.C., Delvys Rodríguez‐Abreu, Maen Hussein, et al.. (2021). LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC. Annals of Oncology. 32. S1428–S1428. 19 indexed citations

10.

Patil, Namrata S., Byoung Chul Cho, Melissa L. Johnson, et al.. (2021). P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC. Journal of Thoracic Oncology. 16(3). S635–S636. 12 indexed citations

11.

Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.. Journal of Thoracic Oncology. 7 indexed citations

12.

Hoang, Tien, et al.. (2020). The Determinants of Listed Commercial Banks’ Profitability in Vietnam. Journal of Asian Finance Economics and Business. 7(11). 219–229. 19 indexed citations

13.

Papadimitrakopoulou, Vassiliki A., Manuel Cobo, Rodolfo Bordoni, et al.. (2018). OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S332–S333. 102 indexed citations

14.

Wakelee, Heather A., Nasser K. Altorki, Eric Vallières, et al.. (2017). P3.02c-050 IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC. Journal of Thoracic Oncology. 12(1). S1305–S1305. 2 indexed citations

15.

Zhang, Yilong, et al.. (2016). Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer. British Journal of Clinical Pharmacology. 83(5). 1048–1055. 5 indexed citations

16.

Vallières, Eric, Enriqueta Felip, Nasser K. Altorki, et al.. (2016). PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC. Journal of Thoracic Oncology. 11(11). S304–S304. 2 indexed citations

17.

Nyflot, Matthew J., Tim J. Kruser, Anne M. Traynor, et al.. (2015). Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion. International Journal of Radiation Oncology*Biology*Physics. 91(5). 942–951. 33 indexed citations

18.

Campbell, Toby C., Tien Hoang, Songwon Seo, et al.. (2011). Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(5). 951–953. 9 indexed citations

19.

Traynor, Anne M., Joan H. Schiller, Laura P. Stabile, et al.. (2008). Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer. 64(1). 51–59. 77 indexed citations

20.

Hoang, Tien, Shyhmin Huang, Eric A. Armstrong, & Paul M. Harari. (2004). Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474. Cancer Research. 64. 955–955. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact